Clinical trial
Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer
NCT06360978 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer
- Lead sponsor
- Assiut University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- April 30, 2024
- Completion date
- June 30, 2027
- Enrollment
- 30 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
head and neck cancer